NCT04916353

Brief Summary

The aim of this study is to investigate the echoguide hypertonic injection and compared steroid injection in subacromial bursitis patients about clinical and ultrasound image presentation.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jun 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 2, 2021

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 7, 2021

Completed
3 days until next milestone

Study Start

First participant enrolled

June 10, 2021

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2021

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

September 5, 2021

Status Verified

September 1, 2021

Enrollment Period

6 months

First QC Date

June 2, 2021

Last Update Submit

September 2, 2021

Conditions

Keywords

Prolotherapysubacromial bursitisultrasound

Outcome Measures

Primary Outcomes (1)

  • Change from Baseline in Shoulder Pain and Disability Index (change of SPADI)

    Shoulder Pain and Disability Index (SPADI), a self-administered assessment tool that was used to measure pain and disability related to shoulder disease. The SPADI consists of 5 pain and 8 disability items that are measured on a visual analog scale. Pain and disability subscales were calculated as the mean of the corresponding items on a 0-100 scale; the highest score indicated the most severe pain and disability. The total outcome score used for statistical analysis was calculated as the sum of the pain and disability subscales.

    Week0 Week2 Week6 Week12

Secondary Outcomes (3)

  • Ultrasound

    Week0 Week2 Week6 Week12

  • Shoulder ROM (Range of Motion)

    Week0 Week2 Week6 Week12

  • Pain (VAS, Visual Analogue Scale)

    Week0 Week2 Week6 Week12

Study Arms (2)

20% hypertonic dextrose water injection group

EXPERIMENTAL

echo guide 20% dextrose water 3ml was injection in lesion site

Drug: hypertonic dextrose water

Steroid injection group

ACTIVE COMPARATOR

Triamcinolone Acetonide 40mg/ml, 1ml, and Lidocaine 2ml as the active comparator group

Drug: Triamcinolone Acetonide.

Interventions

20% hypertonic dextrose water injection for chronic shoulder pain

Also known as: Prolotherapy group
20% hypertonic dextrose water injection group

Triamcinolone Acetonide 40mg/1ml injection

Also known as: comparatice group
Steroid injection group

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Aged more than 20 years old with diagnosis of chronic supraspinatus tendinosis by ultrasound and clinical shoulder pain lasting for more than 3 months.

You may not qualify if:

  • History of shoulder fracture and operation, with frozen shoulder or full thickness ruptur of rotator cuff, steroid, or hyaluronic acid, or platelet rich plasma (PRP) injection during the period of intervention and following up.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Shuang Ho Hospital

New Taipei City, Zhonghe Dist, 235, Taiwan

NOT YET RECRUITING

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

New Taipei City, Zhonghe Dist, 235, Taiwan

RECRUITING

MeSH Terms

Interventions

Triamcinolone Acetonide

Intervention Hierarchy (Ancestors)

TriamcinolonePregnadienesPregnanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSteroids, Fluorinated

Study Officials

  • Lien-Chieh Lin

    Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

    STUDY CHAIR

Central Study Contacts

ShihWei Huang

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Attending Physician

Study Record Dates

First Submitted

June 2, 2021

First Posted

June 7, 2021

Study Start

June 10, 2021

Primary Completion

November 30, 2021

Study Completion

December 31, 2021

Last Updated

September 5, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Locations